Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSANTOS, Gabriel Arantes dos
dc.contributor.authorVIANA, Nayara Izabel
dc.contributor.authorPIMENTA, Ruan
dc.contributor.authorREIS, Sabrina T.
dc.contributor.authorLEITE, Katia Ramos Moreira
dc.contributor.authorSROUGI, Miguel
dc.identifier.citationMEDICAL HYPOTHESES, v.150, article ID 110566, 5p, 2021
dc.description.abstractCurrently, the biggest challenge for prostate cancer (PCa) is to understand the mechanism by which the disease acquires the castration-resistant phenotype and progresses to a fatal disease. PCa has a high genetic heterogeneity, and cannot be separated into well-defined molecular subtypes. Despite this, there is consensus about the role of the androgen receptor (AR) in all stages of the disease, including the transition to the castration-resistant phenotype. Since AR is a transcription factor, we investigated the possibility of PCa presenting a pattern of global gene expression during disease progression. By analyzing the TCGA and CCLE datasets, we were able to find a pattern of waves of genes being expressed during each stage of disease progression. This phenomenon suggests the existence of a mechanism that globally regulates gene expression, being AR, telomeres, and zinc finger proteins (ZNF), three important players. The AR modulates the telomere biology, and its transcription is regulated by ZNF. Recently, a study suggested that the telomere length might influence the expression of ZNF. Thus, we hypothesized that changes in the triad AR, telomeres, and ZNF control gene expression during the progression of PCa.eng
dc.relation.ispartofMedical Hypotheses
dc.subjectGene expression profileeng
dc.subjectCastration-resistant prostate cancereng
dc.subjectZinc finger transcription factoreng
dc.subjectTelomere lengtheng
dc.subjectAndrogen-signaling axiseng
dc.titleHypothesis: The triad androgen receptor, zinc finger proteins and telomeres modulates the global gene expression pattern during prostate cancer progressioneng
dc.rights.holderCopyright CHURCHILL LIVINGSTONEeng
dc.subject.wosMedicine, Research & Experimentaleng
dc.type.categoryoriginal articleeng
hcfmusp.relation.referenceAbeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025eng
hcfmusp.relation.referenceAbildgaard MO, 2012, INT J CANCER, V130, P885, DOI 10.1002/ijc.26097eng
hcfmusp.relation.referenceAviv A, 2003, MECH AGEING DEV, V124, P829, DOI 10.1016/S0047-6374(03)00143-Xeng
hcfmusp.relation.referenceBarretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003eng
hcfmusp.relation.referenceBaydar DE, 2010, PATHOL RES PRACT, V206, P700, DOI 10.1016/j.prp.2010.05.009eng
hcfmusp.relation.referenceChan SRWL, 2004, PHILOS T R SOC B, V359, P109, DOI 10.1098/rstb.2003.1370eng
hcfmusp.relation.referenceChang GTG, 2000, J NATL CANCER I, V92, P1414, DOI 10.1093/jnci/92.17.1414eng
hcfmusp.relation.referenceChen W, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9764752eng
hcfmusp.relation.referenceCohen PA, 2015, ONCOTARGET, V6, P41566, DOI 10.18632/oncotarget.5893eng
hcfmusp.relation.referenceCulig Z, 2014, CANCER METAST REV, V33, P413, DOI 10.1007/s10555-013-9474-0eng
hcfmusp.relation.referenceDai C, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a030452eng
hcfmusp.relation.referencede Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005eng
hcfmusp.relation.referenceDe Vitis M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020606eng
hcfmusp.relation.referenceDemanelis K, 2020, SCIENCE, V369, P1333, DOI 10.1126/science.aaz6876eng
hcfmusp.relation.referenceDing CL, 2020, MOL CELL ENDOCRINOL, V506, DOI 10.1016/j.mce.2020.110745eng
hcfmusp.relation.referenceFordyce CA, 2005, J UROLOGY, V173, P610, DOI 10.1097/01.ju.0000143195.49685.ceeng
hcfmusp.relation.referenceFraser M, 2019, ADV EXP MED BIOL, V1210, P87, DOI 10.1007/978-3-030-32656-2_5eng
hcfmusp.relation.referenceGao S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078766eng
hcfmusp.relation.referenceGiatromanolaki Alexandra, 2019, Curr Urol, V13, P157, DOI 10.1159/000499276eng
hcfmusp.relation.referenceGraham MK, 2017, NAT REV UROL, V14, P607, DOI 10.1038/nrurol.2017.104eng
hcfmusp.relation.referenceHay CW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139990eng
hcfmusp.relation.referenceHeaphy CM, 2020, HUM PATHOL, V101, P70, DOI 10.1016/j.humpath.2020.04.014eng
hcfmusp.relation.referenceHeaphy CM, 2013, CANCER DISCOV, V3, P1130, DOI 10.1158/2159-8290.CD-13-0135eng
hcfmusp.relation.referenceJacob S, 2016, CANCER BIOL THER, V17, P439, DOI 10.1080/15384047.2016.1156255eng
hcfmusp.relation.referenceJen JY, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0269-9eng
hcfmusp.relation.referenceKim SH, 2010, J BIOL CHEM, V285, P10472, DOI 10.1074/jbc.M109.098798eng
hcfmusp.relation.referenceKim W, 2018, DIFFERENTIATION, V99, P1, DOI 10.1016/j.diff.2017.11.005eng
hcfmusp.relation.referenceKirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742-1241.2011.02799.xeng
hcfmusp.relation.referenceLander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062eng
hcfmusp.relation.referenceLin CY, 2018, CANCER SCI, V109, P3564, DOI 10.1111/cas.13776eng
hcfmusp.relation.referenceLiu D, 2004, J BIOL CHEM, V279, P51338, DOI 10.1074/jbc.M409293200eng
hcfmusp.relation.referenceMartinez P, 2010, NAT CELL BIOL, V12, P768, DOI 10.1038/ncb2081eng
hcfmusp.relation.referenceMazzolini R, 2018, NUCLEIC ACIDS RES, V46, P146, DOI 10.1093/nar/gkx958eng
hcfmusp.relation.referenceMeeker AK, 2002, CANCER RES, V62, P6405eng
hcfmusp.relation.referenceMooney SM, 2015, J CELL BIOCHEM, V116, P115, DOI 10.1002/jcb.24948eng
hcfmusp.relation.referenceMukherjee AK, 2019, J BIOL CHEM, V294, P17709, DOI 10.1074/jbc.RA119.008687eng
hcfmusp.relation.referenceMukherjee AK, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007782eng
hcfmusp.relation.referenceNegoita S, 2018, CANCER-AM CANCER SOC, V124, P2801, DOI 10.1002/cncr.31549eng
hcfmusp.relation.referencePimenta Ruan Ca, 2018, Tumour Biol, V40, p1010428318803011, DOI 10.1177/1010428318803011eng
hcfmusp.relation.referenceSchalken J, 2016, BJU INT, V117, P215, DOI 10.1111/bju.13123eng
hcfmusp.relation.referenceSICA G, 1994, UROL RES, V22, P33, DOI 10.1007/BF00431546eng
hcfmusp.relation.referenceSommerfeld HJ, 1996, CANCER RES, V56, P218eng
hcfmusp.relation.referenceTang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430eng
hcfmusp.relation.referenceTolkach Y, 2018, PATHOBIOLOGY, V85, P108, DOI 10.1159/000477852eng
hcfmusp.relation.referenceTownsley DM, 2016, NEW ENGL J MED, V374, P1922, DOI 10.1056/NEJMoa1515319eng
hcfmusp.relation.referenceTreat EG, 2010, UROLOGY, V75, P724, DOI 10.1016/j.urology.2009.04.032eng
hcfmusp.relation.referenceTupler R, 2001, NATURE, V409, P832, DOI 10.1038/35057011eng
hcfmusp.relation.referenceVanaja DK, 2003, CANCER RES, V63, P3877eng
hcfmusp.relation.referenceVukovic B, 2007, CYTOGENET GENOME RES, V116, P1, DOI 10.1159/000097411eng
hcfmusp.relation.referenceWRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-Seng
hcfmusp.relation.referenceWu JC, 2020, MOL CANCER RES, V18, P1326, DOI 10.1158/1541-7786.MCR-19-1129eng
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCG
Departamento de Cirurgia - FM/MCG

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/55
LIM/55 - Laboratório de Urologia

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar

Files in This Item:
File Description SizeFormat 
  Restricted Access
publishedVersion (English)631.95 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.